Clinical Trials
37 trialsCAIRO7
UMC Utrecht
cruciall
Second Affiliated Hospital, School of Medicine, Zhejiang University
HAITI
Gruppo Oncologico del Nord-Ovest
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
Sun Yat-sen University
An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer
Fudan University
Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.
Chinese PLA General Hospital
NIPISAFE
GERCOR - Multidisciplinary Oncology Cooperative Group
Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
Sun Yat-sen University
Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis
Anhui Provincial Cancer Hospital
Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
Treos Bio Limited
Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer
Chinese PLA General Hospital
SHR-1701 Combined with SHR2554 and BP102 for MCRC
Fudan University
Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC
Shanghai Henlius Biotech
SULTAN
UNICANCER
Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA
Fudan University
POCHI
Federation Francophone de Cancerologie Digestive
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Criterium, Inc.
Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer
Sun Yat-sen University
Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer
Vejle Hospital
Local Consolidative Therapy in Colorectal Cancer
Fox Chase Cancer Center
Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
NSABP Foundation Inc
Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects
Istituto Clinico Humanitas
PaSTo
Ospedale San Carlo Borromeo
BEYOND
Grupo Espanol Multidisciplinario del Cancer Digestivo
A Trial of Camrelizumab Combined With Microwave Ablation and Chemotherapy in the Treatment of Colorectal Cancer Liver Metastasis/Pulmonary Metastasis
Harbin Medical University
ZnCORRECT
Chang Gung Memorial Hospital
Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Probat-tmcc-17
University Hospital Rijeka
A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan
Sanofi
Colorectal Cancer (CRC) Cetuximab Elderly Frail
European Organisation for Research and Treatment of Cancer - EORTC
Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma
HaEmek Medical Center, Israel
Gemcitabine in Combination With Pemetrexed Long Term Infusion in the Treatment of Pretreated Metastatic Colorectal Cancer Patients
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
FOIB
Gruppo Oncologico del Nord-Ovest
Drop and Go
Sanofi